| 1 |
35579824 | Prediction of Drug-Drug Interactions After Esketamine Intranasal Administration Using a Physiologically Based Pharmacokinetic Model. | 2022 May 17 |
1 |
| 2 |
35616006 | Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agents. | 2022 May 26 |
1 |
| 3 |
33348240 | The utility of CYP3A activity endogenous markers for evaluating drug-drug interaction between sildenafil and CYP3A inhibitors in healthy subjects. | 2021 Feb |
4 |
| 4 |
33991350 | Population Pharmacokinetic Analysis of Bedaquiline-Clarithromycin for Dose Selection Against Pulmonary Nontuberculous Mycobacteria Based on a Phase 1, Randomized, Pharmacokinetic Study. | 2021 Oct |
2 |
| 5 |
34467456 | Evidence-Based Guidelines for Drug Interaction Studies: Model-Informed Time Course of Intestinal and Hepatic CYP3A4 Inhibition by Clarithromycin. | 2021 Aug 31 |
6 |
| 6 |
34619548 | Reduced theophylline clearance due to hepatic congestion secondary to right heart failure - A population pharmacokinetic study. | 2021 Dec |
1 |
| 7 |
31628882 | Interaction potential between clarithromycin and individual statins-A systematic review. | 2020 Apr |
1 |
| 8 |
32274687 | Evidence of Clinically Meaningful Drug-Drug Interaction With Concomitant Use of Colchicine and Clarithromycin. | 2020 Jul |
1 |
| 9 |
32967779 | Applications of a grid-based CYP3A4 Template system to understand the interacting mechanisms of large-size ligands; part 4 of CYP3A4 Template study. | 2020 Dec |
1 |
| 10 |
30898762 | Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors. | 2019 Mar 26 |
1 |
| 11 |
30920135 | Regulation of drug metabolizing enzymes in the leukaemic bone marrow microenvironment. | 2019 Jun |
2 |
| 12 |
31656654 | Effect of rifampicin and clarithromycin on the CYP3A activity in patients with Mycobacterium avium complex. | 2019 Sep |
2 |
| 13 |
30178440 | The influences of CYP2C9*1/*3 genotype on the pharmacokinetics of zolpidem. | 2018 Sep |
4 |
| 14 |
27822600 | Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens. | 2017 Jan |
1 |
| 15 |
27928738 | Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study. | 2017 Mar |
2 |
| 16 |
28674358 | Acute Kidney Injury from Excessive Potentiation of Calcium-channel Blocker via Synergistic CYP3A4 Inhibition by Clarithromycin Plus Voriconazole. | 2017 |
2 |
| 17 |
26668209 | Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters. | 2016 Mar |
1 |
| 18 |
27236320 | Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole. | 2016 Dec |
1 |
| 19 |
25429094 | Calcium channel blocker-clarithromycin drug interaction did not increase the risk of nonvertebral fracture: a population-based study. | 2015 Feb |
1 |
| 20 |
25534598 | Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. | 2015 Feb 17 |
3 |
| 21 |
25915157 | Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes. | 2015 Jun 20 |
1 |
| 22 |
25976224 | The enhancement of cardiac toxicity by concomitant administration of Berberine and macrolides. | 2015 Aug 30 |
1 |
| 23 |
26497728 | A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death. | 2015 Oct 24 |
1 |
| 24 |
26819743 | Serum concentrations of clarithromycin and rifampicin in pulmonary Mycobacterium avium complex disease: long-term changes due to drug interactions and their association with clinical outcomes. | 2015 |
4 |
| 25 |
23738582 | Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers. | 2014 Jan |
1 |
| 26 |
24035278 | Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis. | 2014 Mar |
3 |
| 27 |
25041770 | Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin. | 2014 Jul |
2 |
| 28 |
25106415 | Clinical CYP3A inhibitor alternatives to ketoconazole, clarithromycin and itraconazole, are not transported into the liver by hepatic organic anion transporting polypeptides and organic cation transporter 1. | 2014 Nov |
2 |
| 29 |
25359648 | Vitamin and mineral supplements: friend or foe when combined with medications? | 2014 Nov |
1 |
| 30 |
25571290 | A pharmacokinetic drug-drug interaction model of simvastatin and clarithromycin in humans. | 2014 |
1 |
| 31 |
22777148 | Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin. | 2013 Mar |
7 |
| 32 |
23462027 | Colchicine-antimicrobial drug interactions: what pharmacists need to know in treating gout. | 2013 Mar |
1 |
| 33 |
23514827 | Mechanism-based inhibition profiles of erythromycin and clarithromycin with cytochrome P450 3A4 genetic variants. | 2013 |
3 |
| 34 |
23778904 | Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. | 2013 Jun 18 |
4 |
| 35 |
23847265 | Comparing two types of macrolide antibiotics for the purpose of assessing population-based drug interactions. | 2013 |
1 |
| 36 |
24252529 | [Pharmacokinetic interactions]. | 2013 Jun |
1 |
| 37 |
24346990 | Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. | 2013 Dec 18 |
1 |
| 38 |
25011542 | Retrospective analysis of severe neutropenia in patients receiving concomitant administration of docetaxel and clarithromycin. | 2013 |
1 |
| 39 |
22170330 | Clarithromycin is absorbed by an intestinal uptake mechanism that is sensitive to major inhibition by rifampicin: results of a short-term drug interaction study in foals. | 2012 Mar |
2 |
| 40 |
22372724 | Use of clarithromycin and adverse cardiovascular events among older patients receiving donepezil: a population-based, nested case-control study. | 2012 Mar 1 |
1 |
| 41 |
22644980 | Risk of hypotension with concomitant use of calcium-channel blockers and macrolide antibiotics. | 2012 Jun 15 |
1 |
| 42 |
28520375 | Aripiprazole Therapy and CYP2D6 Genotype | 2012 |
1 |
| 43 |
21242274 | The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers. | 2011 Feb 22 |
1 |
| 44 |
21480191 | Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. | 2011 Aug |
1 |
| 45 |
22009620 | The difficulties of polytherapy: examples from antimicrobial chemotherapy. | 2011 Oct |
2 |
| 46 |
19884323 | Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. | 2010 Feb |
9 |
| 47 |
19897389 | Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine. | 2010 Jul |
3 |
| 48 |
19943026 | [Interactions with antiretroviral drugs]. | 2010 Jan |
1 |
| 49 |
20305307 | [Complex hallucination (visual-auditory) during coadministration of tramadol and clarithromycin]. | 2010 Mar |
1 |
| 50 |
20446912 | Assessment of competitive and mechanism-based inhibition by clarithromycin: use of domperidone as a CYP3A probe-drug substrate and various enzymatic sources including a new cell-based assay with freshly isolated human hepatocytes. | 2010 Apr |
2 |